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Abstract
Up to 60% of untreated atypical hyperplastic endometrium will develop into endometrial carcinoma (EC), and for those who
underwent a hysterectomy a coexisting EC is found in up to 50%. Gene promoter methylation might be related to the EC
development. The aim of this study is to determine changes in gene promoter profiles in normal endometrium, atypical hyper-
plasia (AH) and EC in relation to K-Rasmutations. A retrospective study was conducted in patients diagnosed with endometrial
hyperplasia with and without subsequent EC. Promoter methylation of APC, hMLh1, O6-MGMT, P14, P16, RASSF1, RUNX3
was analysed on pre-operative biopsies, and correlated to the final histological diagnosis, and related to the presence of K-Ras
mutations. In the study cohort (n=98), differences in promoter methylation were observed for hMLH1, O6-MGMT, and P16.
Promoter methylation of hMLH1 and O6-MGMT gradually increased from histologically normal endometrium to AH to EC;
27.3, 36.4% and 38.0% for hMLH1 and 8.3%, 18.2% and 31.4% for O6-MGMT, respectively. P16 promoter methylation was
significantly different in AH (7.7%) compared to EC (38%). K-Ras mutations were observed in 12.1% of AH, and in 19.6% of
EC cases. No association of K-Ras mutation with promoter methylation of any of the tested genes was found. In
conclusion, hMLH1 and O6-MGMT promoter methylation are frequently present in AH, and thus considered to be early events
in the carcinogenesis of EC, whereas P16 promoter methylation was mainly present in EC, and not in precursor lesions
supporting a late event in the carcinogenesis.
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Abbreviations
APC APC Adenomatous polyposis coli
hMLH1 Human mutL homolog 1
O6-MGMT O-6-methylguanine-DNA methyltransferase
P14 Cyclin-dependent kinase inhibitor 2A (alter-
native reading frame)
P16 Cyclin-dependent kinase inhibitor 2A
RASSF1 Ras association (RalGDS/AF-6) domain fam-
ily member 1
RUNX3 Runt-related transcription factor 3
K-Ras proto-oncogene
Introduction
Endometrial cancer (EC) is the most common malignancy of
the female genital tract in Europe and North America. In the
Netherlands every year approximately 1,900 women are diag-
nosed with EC with a mortality rate of approxmately 400
women [1]. The incidence of EC has increased markedly dur-
ing the last decades, due to both an increased life-expectancy
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and obesity [2]. The so-called type I tumours (i.e. typically
low grade endometrioid subtype) are thought to be induced by
unopposed estrogen stimulation of the endometrium resulting
in hyperplasia with or without atypia, with subsequently pro-
gression into EC [3, 4]. The risk of endometrial hyperplasia
and progression to cancer is related to the presence of cellular
atypia. In 2014 the World health organisation described a new
classification system to distinguish endometrial hyperplasia,
abandoning the previously used distinction between simple
and complex hyperplasia and focusing solely on the presence
or absence of atypia [5]. The risk of developing EC when
endometrial hyperplasia without atypia is present is around
3%, and increases up to 60% in atypical endometrial hyper-
plasia (AH). Epigenetic studies explain this risk difference by
the observation of no epigenetic changes in hyperplasia with-
out atypia, compared to multiple epigenetic changes in hyper-
plasia with atypia [4–12].
It is noteworthy that in up to 50% of performed hysterec-
tomies for AH a coexistent EC is found [6, 10, 12–14].
Although the majority of these ECs are diagnosed at an early
stage, low histological grade and low stage of disease, Giede
et al described a 16% chance of high risk EC, histological
grade 2, and advanced stage disease, in patients pre-
operatively diagnosed with only AH [14]. The presence of a
coexistent carcinoma may alter the surgical treatment ap-
proach. In addition, 20% of patients with these type I tumours,
that develop out of endometrial hyperplasia, with, a presumed
good outcome, present with recurrent disease [8, 9, 14].
Understanding of the progression from AH to EC might con-
tribute to improved selection for hormonal treatment for fer-
tility preservation for young patients, as well as for patients
that are not suitable for surgery due to comorbidity.
Gene promoter methylation is frequently present in en-
dometrial carcinoma, mainly in type I EC. Promoter meth-
ylation of hMLH1, APC and RASSF1A are considered to be
early events in endometrial carcinogenesis [8, 9, 15–21].
Arafa et al. demonstrated that even in normal endometrium,
adjacent to the endometrioid adenocarcinoma, a high fre-
quency of RASSF1A and RARb2 promoter methylation was
observed [22]. Berg et al. demonstrated that K-Ras and
PI3K activation, loss of PTEN, and PIK3CA mutations are
also early events in the endometrial carcinogenesis and are
often present AH lesions. This supports the hypothesis that
in AH (epi)genetic mutations are already present, which
may result in the progression to endometrial carcinoma
[23, 24]. There is evidence that in colorectal cancer and
lung carcinoma O6-MGMT hypermethylation precedes K-
Ras mutations [20, 25]. In EC it is shown that K-Ras muta-
tions are closely related to micro satellite instability (MSI)
[26]. These data, as well as the fact that estrogen is consid-
ered to be an epimutagen, support the fact that epigenetic
alterations may be an important mechanism in the progres-
sion of endometrial hyperplasia into cancer [27].
The purpose of the current study was to determine gene
promoter methylation patterns in pre-hysterectomy histologi-
cal samples of patients with endometrial hyperplasia diag-
nosed by endometrial sampling prior to hysterectomy, in rela-
tion to their final pathological diagnosis. Furthermore, K-Ras
mutations were analysed and correlated to gene methylation
profile.
Material and Methods
Patients and Tissue Specimens
All patients diagnosed with endometrial hyperplasia; simple
or complex hyperplasia with or without atypia between 1996
and 2011 at the departments of pathology of the Maastricht
University Medical Centre and the Elisabeth-Tweesteden hos-
pital Tilburg, who underwent hysterectomy within 9 months
after endometrial sampling, were retrieved by the Dutch
National Pathology Register (PALGA). All specimens were
handled in a coded fashion as prescribed by the Dutch national
guidelines for secondary use of specimen (BHuman Tissue and
Medical Research: Code of conduct for responsible use^).
Histology from the endometrium sampling and final histology
and diagnosis after hysterectomy were systematically
reviewed by one of the two pathologists (KvdV, AvdW) ac-
cording to the WHO 2014 classification [28, 29]. Histology
prior to surgery was obtained by endometrial aspiration, hys-
teroscopic guided biopsy or dilatation & curettage (D&C). In
patients with more than one sample the last sample before
surgery was used for analysis.
Clinical and pathological characteristics were collected
from the patient’s medical charts including: age at diagnosis,
Body Mass index (BMI), parity, use of hormonal replacement
therapy (HRT), hypertension, diabetes mellitus, menopausal
state, smoking, time till hysterectomy, final histopathological
diagnosis and FIGO 2009 stage [30]. Final diagnosis was
prescribed according to the RCOG Guideline ‘Management
of hyperplasia’ [29]; normal endometrium (pre- and postmen-
opausal), endometrial hyperplasia without atypia, endometrial
hyperplasia with atypia (AH) and endometrial carcinoma
(EC), as illustrated in Fig. 1. All patients were treated by
hysterectomy and bilateral salpingo-oophorectomy. The study
was approved by the Medical Ethical Committee of the
Maastricht University Medical Center and the Elisabeth-
Tweesteden hospital, Tilburg.
DNA Isolation
After identification of the area of normal endometrium, atyp-
ical hyperplasia or EC by the pathologist, tissue was manually
dissected from five consecutive 20 μm sections of the paraffin
embedded tissue. Genomic DNA was extracted using a
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proteinase K (Qiagen) digestion followed by DNA isolation
using the Puregene DNA Isolation Kit (Gentra Systems).
Gene Promoter Methylation Analysis
DNA methylation in the CpG island of the genes was deter-
mined as described previously [31] and investigated for the
following genes; APC, hMLh1, O6-MGMT, P14, P16,
RASSF1, RUNX3. To enable MSP analysis on DNA retrieved
from formalin-fixed, paraffin embedded tissue, a nested MSP
was performed as described by van Engeland et al. [32]. All
MSP’s were performed with a control for unmethylated alleles
(DNA from normal lymphocytes), a control for methylated
alleles (in vitro methylated DNA of normal lymphocytes treat-
ed with Sssl methyltransferase (New England Biolabs)) and a
negative control (H2O). A total of 6 μl of each MSP reaction
was loaded on a non-denaturing 6% polyacrylamide gel,
stained with ethidium bromide and visualised under UV illu-
mination. The presence of a PCR product in respectively the U
and M lane indicates the presence of unmethylated or meth-
ylated alleles. Cases methylated in one of two cases were
considered as methylated. The primer sets for all tested genes
are listed in Supplementary table 1.
K-Ras Mutation
As a template for K-Ras codon 12 and 13 a 179 bp product
was amplified and used as a template for the amplification of a
114 bp fragment. 250 ng genomic DNA was added to 50
mmol/l MgCl2, 18.15 μl MQ, 2.50 μl PCR buffer (10x),
0.25 μl deoxynucleoside triphosphate (dNTP) (Pharmacia,
Uppsala, Sweden), 0.25 μl of Flank primers F 5′-AGGC
CTGCTGAAAATGACTGAATA-3 ′ and 5 ′ -CTGT
ATCAAAGAATGGTCCTGCAC-3′, and 0.1 μl platinum-
Taq 5 U/l (Invitrogen, Breda, The Netherlands) (annealing
temperature 50_C).
The final analyses were performed with 5 μl 100x dilution
(1:100 2μl PCR product in 198 ul 0.1xTE), 18.4 μl MQ,
Fig. 1 Histology of the
endometrium. a Normal
proliferative endometrium in a
pre-menopausal period. b Normal
endometrium with cystic atrophy
(post-menopausal). c and d
Atypical endometrial hyperplasia
(^), adjacent to normal
endometrium (*). e Endometrioid
endometrial carcinoma, grade 1
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2.5 μl PCR buffer (10x), 0.75 μl 50 mmol/l MgCl2, 0.25 μl
dNTP, 0.25μl of primers 5′-AAAATGACTGAATATAAACT
TGTGG-3 and 5′-CTCTATTGTTGGATCATATTCGTC-3′
and 0.1 μl platinum- Tag 5 U/l.
Electrophoresis on 2% agarose gels was used to check the
size and amount of the PCR products. Clean up was per-
formed using 2 μl ExoSAP-IT kit (product number 78201)
with 5 μl PCR product. Sequencing reaction was performed
using the Big Dye sequencing 1.1 kit (1.5 μl Big Dye buffer,
1 μl Big Dye mix, 1.6 μl primer 1 μM (5′ TGTAAAAC
GACGGCCAGT 3′ and 5′ CAGGAAACAGCTATGACC
3′), 4.9 μl MilliQ added to 1 μl cleaned up PCR product).
Afterward the PCR products were separated.
Primary Outcome
Primary outcome was defined as the differences in gene pro-
moter methylation between normal endometrium, AH and EC
in the pre-operative samples.
Secondary Outcome
Secondary outcome was defined as the correlation of gene
promoter methylation with the presence of K-Ras mutations
and clinicopathological factors.
Data Analysis
The SPSS software program (22.0) was used for statistical
analysis. Median values were calculated for the patient’s age
and BMI. To test whether the differences for gene promoter
methylation and K-Ras mutation between the three patient
groups (normal endometrium, AH and EC) were significant,
ANOVAwith post HOC analyses were performed.
All tests of statistical significance were two-sided, and a p-
value of 0.05 was considered significant.
Results
Patient Characteristics
A total of 99 patients met the inclusion criteria. Patients were
classified in three different groups based on the final histolog-
ical examination of the hysterectomy specimen categorized as
normal endometrium, AH and EC (Fig. 1). One patient with
simple hyperplasia without atypia was excluded to optimize
the homozygosity of our study cohort resulting in 98 suitable
for analysis. Patient characteristics according to final patholo-
gy are shown in Table 1.
The mean age of the study cohort was 62 years (35-93)
with a mean BMI of 30.9 kg/m2 (19.0-43.0). The majority
(79%) of patients were postmenopausal at time of diagnosis.
Table 1 Patient characteristics










Age at time of
hysterectomy (mean)in
years
57 (40-76) 64 (41-93) 63 (35-84) p<0.05*















Table 1 * Significant difference between normal endometrium and atypical endometrial hyperplasia p=0.041,. n.s.
= not statistically significant. n.a. not applicable
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There was a only statistical significant difference in age at
the time of hysterectomy between the patients with normal
endometrium compared to patients with atypical endometrial
hyperplasia.
Table 2 shows the correlation between the pre-operative
histological diagnosis and the final post-operative histological
diagnosis. The agreement between the pre- and post-operative
histological diagnosis was 55%. In 35% of cases there was an
upgrade of the pre-operative histological diagnosis and in
10% there was a downgrade of the pre-operative diagnosis
(Table 3).
Gene Promoter Methylation
Results of the percentages of gene promoter methylation for
the tested genes are illustrated in Fig. 2, according the endo-
metrial tissue: normal endometrium, atypical hyperplastic en-
dometrium, endometrial carcinoma. For hMLH1 (n=96) a
non-statistically significant increase in promoter methylation
was seen in the development from normal endometrium toAH
into EC:, 27,3% (n=3), 36.4% (n=12) and 38.0% (n=19). A
comparable pattern was seen for O6-MGMT (n=96) with pro-
moter methylation in 8.3% (n=1), 18.2 % (n=6) and 31.4%
(n=16) respectively. There was a significant increase in pro-
moter methylation for P16 (n=70) in patients with EC 38.2 %
(n=13) compared to AH 7.7% (n=2) (p<0.05). The difference
in methylation between normal endometrium (10% n=1) com-
pared to AH is not significantly different. The APC (n= 96)
promoter methylation was more frequently present in patients
with AH 42.4 % (n=14) compared to the patients with EC
19.6% (n=10) and was significantly different (p<0.05). No
significantly difference was seen for normal endometrium
(33.3% n=4) compared to AH and/or EC.
For all other tested genes: p14 (n=94), RASSF1 (n=94),
RUNX3 (n=95) no pattern in gene promoter methylation be-
tween normal endometrium, atypical endometrial hyperplasia
and EC was seen.
K-Ras Mutations
K-Ras analysed was performed in a total of 99 cases. In none
of the patients with the diagnosis normal endometrium (n=14)
K-Ras mutations were found, whereas K-Ras mutations were
found in AH and EC in respectively 12.1% (4/33) and 19.6%
(10/51). The difference was not statistically significant.
In Fig. 3 the results ofK-Rasmutations and promoter meth-
ylation for hMLH1, O6-MGMT, and P16 are summarized.
BMI, age and tumour grade were not significantly related with
the promoter methylation of any of the tested genes.
Data of the K-Ras mutations in relation to hMLH1, O6-
MGMT and P16 promoter methylation for both AH and EC
are presented in Supplementary Table 2.
Discussion
In the current study we have demonstrated that promoter
methylation of hMLH1 and 06-MGMT was frequently seen
in premalignant endometrial tissue, whereas P16 promoter
methylation was more frequently observed in EC. Also K-
Ras mutations were present in AH, yet these mutations were
not related to any of the promoter methylated genes.
Table 3 Individual relation between K-Ras mutation and 06-MGMT,
















1 yes no no
2 no unkown no
3 yes yes no
4 yes unknown no
Endometrial
carcinoma
5 no yes no
6 no yes yes
7 no no no
8 no no no
9 no unknown yes
10 no no no
11 no no no
12 yes yes no
13 yes no yes
14 yes no yes
Table 2 Pre-operative histological diagnosis compared to final
histological diagnosis





Normal endometrium (NE) (N=17) NE 2
AH 1
EC 14
Atypical endometrial hyperplasia (AH) (N=72) NE 9
AH 44
EC 19
Endometrial carcinoma (EC) (N=9) NE
AH 1
EC 8
Table 2 Nl = normal endometrium, hyp = atypical hyperplastic endome-
trium, EC = endometrial cancer
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Although gene promoter methylation has frequently been
described in EC, data in precursor lesions are limited.
The hMLH1 is one of the genes involved in the DNA mis-
match repair mechanism and related to microsatellite instabil-
ity (MSI) in several cancers. We observed hMLH1 promoter
methylation in 38% of EC cases, which is in accordance with
previous studies [7, 8, 33]. Additionally, in AH we found
promoter methylation in 36.4%, and even in 25% of normal
endometrial tissue hMLH1 promoter methylation was found,
in contrast to previous studies that did not identify promoter
methylation in normal endometrium [7, 8, 34].
Esteller et al. showed a relation between hMLH1 pro-
moter methylation and MSI. In their study they showed 7
out of 21 AH cases positive for hMLH1 promoter meth-
ylation, (33.3%) in line with our data. Furthermore, 40%
of EC showed hMLH1 promoter methylation and in 91%
of the cases MSI was seen. Guida et al. showed that es-
pecially the combination of hMLH1 promoter methylation
and P16 promoter methylation is more frequently seen in
endometrial hyperplasia and endometrial carcinoma com-
pared to normal endometrium [14, 15, 34].
The presence ofMSI caused bymismatch repair deficiency
either through gene promoter methylation or gene mutation
seems clinically relevant. A strong relation between the ex-
pression of the programmed cell death 1 protein (PD-1) and
programmed cell death 1 ligand 1 (PD-L1) as well as tumour-
infiltrating lymphocytes (CD8+) and MSI was recently dem-
onstrated [35, 36]. This might indicate that immune check-
point inhibitors (anti-PD-1/PD-L1 antibody) could be effec-
tive in endometrial cancers with MSI. The presence of MSI
may be a biomarker for good response to PD-1/PD-L1 immu-
notherapy in endometrial cancer [35, 36].
O6-MGMT is known to play an important role in the
carcinogenesis for different type of tumours. In normal
cells it’s involved in DNA damage repair and prevent
mismatch errors during DNA transcription and replica-
tion. Increased gene promoter methylation and thereby
silencing of this gene may result in progression to the
development of neoplasms. In the present study we
found a trend of increased promoter methylation for the
O6-MGMT from normal endometrium (8.3%) into endo-
metrial carcinoma (31.4%), which is in accordance with
two other studies [12, 15]. In contrast, Rimel et al. did
not found any O6-MGMT promoter methylation in 120





Fig. 2 Percentage of gene
promoter methylation according
to final pathology. Gene promoter
methylation in percentage
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K-RAS mutation  
Normal  Hyperplasia  Carcinoma  
Fig. 3 Promoter methylation for
P16, hMLH1, and 06-MGMT,
and K-Ras mutation according to
final pathological classification
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In our study we observed a significant increase of P16
promoter methylation from AH to EC, which supports the
hypothesis that P16 promoter methylation might contribute
to the development of EC. The tumour suppressor P16 acts
as a tumour suppressor that inhibits the cyclin-dependent ki-
nase 2A, resulting in cell cycle arrest, and consequently, pro-
moter methylation of P16 consequently results in cell growth
and proliferation. In our study cohort P16 promoter methyla-
tion was found to increase from normal endometrium to EC.
Previous studies showed conflicting results of the P16 pro-
moter methylation in normal endometrium.Most studies show
no gene promoter methylation at all [39–41]. Banno et al. did
not observe any P16 promoter methylation in his series of 92
cases including normal, premalignant and malignant endome-
trial tissue [8, 15].
Salvesen et al. showed P16 promoter methylation in one
out of 138 EC cases, however most of these cases were high
grade EC, which are assumed to be more frequently related to
p53mutations than to epigenetic factors [40]. In addition, low
grade EC development is known to be specifically related to
precursor lesions such as atypical hyperplasia and is known to
be related to intracellular estrogen levels, whereas for high
grade EC the carcinogenesis is different [42]. The same results
are seen by Yanokura et al., who investigated 17 EC mostly
high grade ECs and did not find any promoter methylation in
those cases [41]. Others have shown P16 promoter methyla-
tion in up to 75% [15, 33, 34, 39–41]. Hu et al. performed a
meta-analysis including 6 studies and showed an Odds ratio of
13.5 (97% CI 5.5-33.3) for the relation between P16 promoter
methylation and EC, although the type of EC was not speci-
fied in this series. These data suggest that P16 promoter meth-
ylation is late event in the carcinogenesis of endometrioid EC
and therefore interesting with respect to its low presence in
AH and patients prognosis.
Current data support the existing data that hMLH1 andO6-
MGMT promoter methylation are early events in de progres-
sion from normal endometrium into endometrial cancer.
Whereas P16 promoter methylation is showed to be a late
event in EC development.
We found an increased rate of K-Ras mutation for AH
compared to endometrial cancer cases. No K-Rasmutations
were found in patients with a final diagnosis of normal
endometrium. K-Ras mutations are frequently seen in com-
bination with microsatellite instability (MSI) [43–45]. Van
der Putten et al. studied the presence of K-Ras mutations in
EC and the adjacent endometrial tissue and found increased
mutation rates in EC with adjacent hyperplastic endometri-
um, but not in EC with adjacent atrophic endometrium.
This suggests a role for K-Ras mutation in the development
of endometrioid EC.
The strength of this study is the homogenous groups of AH
cases and low-grade endometrioid ECs. Furthermore our
group of controls consists of mostly postmenopausal women
and, because the increased incidence of endometrial cancer in
the post-menopausal period, this is of important value when
discussing the development of endometrial cancer.
Limitations of the study are the relatively small sample
size, the control group not being matched to the cases in re-
garding to age and BMI, although the latter did not differ
between groups.
Clinical Implications
Epigenetic alterations in precursor lesions of EC may be clin-
ically relevant to estimate the risk of a coexisting carcinoma,
as well as contribute to the response of hormonal treatment for
those women who would like to preserve fertility, and those
who have an increased risk for surgery.
Conclusion
hMLH1 andO6-MGMT promoter methylation andK-Rasmu-
tation seem to be early events in the carcinogenesis of EC and
are frequently present in atypical endometrial hyperplasia.
Whereas P16 promoter methylation is mainly present in EC,
and not in precursor lesions supporting as a late event in the
EC carcinogenesis. These data support the importance of epi-
genetic changes in de development of EC.
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